Companies Trevi Therapeutics, Inc.
Trevi Therapeutics (TRVI): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Trevi Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,687,298FY2023
- $2,589,035FY2024
- $3,944,892FY2025
CEO total pay was $3,944,892 in fiscal 2025, up from $2,589,035 in fiscal 2024.
FY2025: salary $622,382 · bonus $343,750 · stock awards $0 · option awards $2,968,260
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jennifer Good | $622,382 | $343,750 | $0 | $2,968,260 | $0 | $0 | $10,500 | $3,944,892 |
| President and Chief Executive Officer | ||||||||
| James Cassella | 488,270 | 196,000 | 0 | 942,450 | 0 | 0 | 10,500 | 1,637,220 |
| Chief Development Officer | ||||||||
| Farrell Simon | 370,067 | 150,000 | 0 | 825,330 | 0 | 0 | 10,500 | 1,355,897 |
| Chief Commercial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jennifer Good | $3,944,892 | $2,589,035 | $1,687,298 | ↑ +1,355,857 |
| James Cassella | 1,637,220 | 1,441,119 | — | ↑ +196,101 |
| Farrell Simon | 1,355,897 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to attract and retain qualified and talented executives, motivate such executives to achieve our business goals and reward them for short- and long-term performance with a simple and clear compensation structure.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Farrell Simon | Option | 3,125 | 0.51 | — |
| Jennifer Good | Option | 11,459 | 0.51 | — |
| Farrell Simon | Option | 29,167 | 2.67 | — |
| Farrell Simon | Option | 94,792 | 2.38 | — |
| Jennifer Good | Option | 109,375 | 2.67 | — |
| Farrell Simon | Option | 225,500 | 4.22 | — |
| James Cassella | Option | 257,500 | 4.22 | — |
| James Cassella | Option | 275,000 | 3.34 | — |
| Jennifer Good | Option | 341,250 | 2.38 | — |
| Jennifer Good | Option | 811,000 | 4.22 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| David Meeker, M.DIndependent · Nominating and Corporate Governance | $75,000 | $0 | $218,430 | — | $0 | $293,430 |
| Michael HeffernanIndependent · Audit · Compensation (Chair) | 65,000 | 0 | 218,430 | — | 0 | 283,430 |
| Anne VanLentIndependent · Audit (Chair) · Nominating and Corporate Governance | 65,000 | 0 | 218,430 | — | 0 | 283,430 |
| Dominick ColangeloIndependent · Audit · Compensation | 57,500 | 0 | 218,430 | — | 0 | 275,930 |
| Edward MathersIndependent · Compensation | 47,500 | 0 | 218,430 | — | 0 | 265,930 |
| Jennifer GoodEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $310,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $310,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Trevi Therapeutics as a peer
Companies that benchmark against TRVI
3 companies name TRVI as a compensation peer
The list of companies that name TRVI as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Janux Therapeutics | 2025 | David Campbell | $680,000 | $0 | $12,459,031 | $367,200 | $13,506,231 |
| 2 | Centessa Pharmaceuticals | 2025 | Saurabh Saha | 683,884 | 0 | 10,755,360 | 0 | 11,877,244 |
| 3 | Dianthus Therapeutics | 2025 | Marino Garcia | 630,000 | 0 | 9,450,952 | 519,750 | 10,614,702 |
| 4 | Edgewise Therapeutics | 2025 | Kevin Koch | 670,000 | 1,171,625 | 5,041,621 | 462,300 | 7,359,546 |
| 5 | Spyre Therapeutics | 2025 | Cameron Turtle | 665,000 | 0 | 5,552,886 | 475,475 | 6,707,361 |
| 6 | Astria Therapeutics | 2024 | Jill Milne | 637,868 | 0 | 5,637,078 | 318,934 | 6,604,416 |
| 7 | Rapport Therapeutics | 2025 | Abraham Ceesay | 652,927 | 0 | 5,156,416 | 431,059 | 6,265,174 |
| 8 | AnaptysBio | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 9 | Rezolute | 2026 | Nevan Charles Elam | 655,000 | 3,220,720 | 1,358,972 | 0 | 5,711,410 |
| 10 | Mineralys Therapeutics | 2025 | Jon Congleton | 636,500 | 0 | 4,435,626 | 472,601 | 5,544,727 |
| 11 | Celldex Therapeutics | 2025 | Anthony Marucci | 785,804 | 0 | 4,027,590 | 0 | 5,366,709 |
| 12 | Savara | 2025 | Matthew Pauls | 660,000 | 3,870,000 | 0 | 297,000 | 4,845,000 |
| 13 | Anavex Life Sciences | 2025 | Christopher Missling | 723,485 | 0 | 3,083,000 | 0 | 3,959,085 |
| 14 | Trevi Therapeutics, Inc. | 2025 | Jennifer Good | 622,382 | 0 | 2,968,260 | 0 | 3,944,892 |
| 15 | Kodiak Sciences | 2025 | Victor Perlroth | 792,497 | 0 | 923,032 | 772,824 | 2,499,221 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Trevi Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| AnaptysBio | 110% | not disclosed | No | Alpine Rewards |
| Anavex Life Sciences | not disclosed | Option 100 | not disclosed | not disclosed |
| Astria Therapeutics | not disclosed | Option 100 | not disclosed | Aon |
| Celldex Therapeutics | 100% | Options 100 | not disclosed | Aon (Human Capital Solutions practice, a division of Aon plc) |
| Centessa Pharmaceuticals | not disclosed | not disclosed | not disclosed | not disclosed |
| Dianthus Therapeutics | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Edgewise Therapeutics | not disclosed | not disclosed | not disclosed | Alpine |
| Janux Therapeutics | 90% | not disclosed | not disclosed | FW Cook |
| Kodiak Sciences | 150% | not disclosed | not disclosed | Compensia, Inc. |
| Mineralys Therapeutics | not disclosed | Option 100 | not disclosed | not disclosed |
| Rapport Therapeutics | not disclosed | not disclosed | not disclosed | Aon PLC |
| Rezolute | not disclosed | not disclosed | not disclosed | not disclosed |
| Savara | 90% | RSU 100 | not disclosed | Aon |
| Spyre Therapeutics | 130% | Option 100 | not disclosed | Alpine Rewards |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-03 | 98,119,461 | 1,982,126 | 101,904 | 98.02% | Passed |
| 2025 | 2025-06-11 | 78,346,572 | 722,449 | 26,248 | 99.09% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-03 | 98.02%a |
| 2025 | 2025-06-11 | 99.09%b |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (28 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Jennifer Good. DEF 14A, filed 2026-04-21. Section “Executive Compensation” · page 30. As printed: 3,944,892. View filing ↗
- Section 01, James Cassella. DEF 14A, filed 2026-04-21. Section “Executive Compensation”. As printed: 1,637,220. View filing ↗
- Section 01, Farrell Simon. DEF 14A, filed 2026-04-21. Section “Executive Compensation”. As printed: 1,355,897. View filing ↗
- Section 08, David Meeker, M.D. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 293,430. View filing ↗
- Section 08, Michael Heffernan. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 283,430. View filing ↗
- Section 08, Anne VanLent. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 283,430. View filing ↗
- Section 08, Dominick Colangelo. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 275,930. View filing ↗
- Section 08, Edward Mathers. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 265,930. View filing ↗
- Section 08, Jennifer Good. DEF 14A, filed 2026-04-21. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-04. Item 5.07 · say-on-pay result. As reported: 98.02% (votes for as printed: 98,119,461). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-17. Item 5.07 · say-on-pay result. As reported: 99.09% (votes for as printed: 78,346,572). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 310,000 + equity 0 + all other 0 = 310,000, summed across the director compensation table rows.
- Janux Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Janux Therapeutics's own proxy. As printed: 13,506,231. View filing ↗
- Centessa Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Centessa Pharmaceuticals's own proxy. As printed: 11,877,244. View filing ↗
- Dianthus Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Dianthus Therapeutics's own proxy. As printed: 10,614,702. View filing ↗
- Edgewise Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Edgewise Therapeutics's own proxy. As printed: 7,359,546. View filing ↗
- Spyre Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Spyre Therapeutics's own proxy. As printed: 6,707,361. View filing ↗
- Astria Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Astria Therapeutics's own proxy. As printed: 6,604,416. View filing ↗
- Rapport Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Rapport Therapeutics's own proxy. As printed: 6,265,174. View filing ↗
- AnaptysBio, Section 10b CEO total. DEF 14A, filed 2026-06-29. CEO total compensation as printed in AnaptysBio's own proxy. As printed: 6,133,943. View filing ↗
- Rezolute, Section 10b CEO total. DEF 14A, filed 2026-10-21. CEO total compensation as printed in Rezolute's own proxy. As printed: 5,711,410. View filing ↗
- Mineralys Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Mineralys Therapeutics's own proxy. As printed: 5,544,727. View filing ↗
- Celldex Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Celldex Therapeutics's own proxy. As printed: 5,366,709. View filing ↗
- Savara, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Savara's own proxy. As printed: 4,845,000. View filing ↗
- Anavex Life Sciences, Section 10b CEO total. DEF 14A, filed 2026-08-11. CEO total compensation as printed in Anavex Life Sciences's own proxy. As printed: 3,959,085. View filing ↗
- Trevi Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in Trevi Therapeutics, Inc.'s own proxy. As printed: 3,944,892. View filing ↗
- Kodiak Sciences, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Kodiak Sciences's own proxy. As printed: 2,499,221. View filing ↗